HeartBeam Granted Patent for 12-Lead Electrocardiogram (ECG) Patch Monitor Intended for Detection of Heart Attacks and Complex Cardiac Arrhythmias
September 15 2022 - 8:31AM
Business Wire
Patent Opens Pathway to a Disruptive
Ischemia and Arrhythmia Detection ECG Patch Product
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology
company that has developed the first and only 3D-vector ECG
platform for heart attack detection anytime, anywhere, announced
today that its patent for a 12-lead electrocardiogram (ECG) patch
monitor intended for detection of acute coronary syndrome (ACS) and
cardiac arrhythmia was issued by the United States Patent and
Trademark Office. The innovation builds on HeartBeam’s growing
intellectual property portfolio enabling 12-lead ECG diagnostics
outside of a medical setting.
The global ECG patch monitor market, estimated to reach $4.8B by
2030, is currently limited to arrhythmia detection via the use of
single-lead ECG devices. By elevating patch monitor technology with
a synthesized 12-lead ECG, HeartBeam can aid physicians in both
arrhythmia detection and ACS diagnosis including myocardial
infarction (heart attack) and angina.
“This patent provides additional intellectual property
protection for our breakthrough ECG patch technology, offering
12-lead ECG capability in the form of a simple patch that is
similar in size and shape to existing single-lead ECG patch
monitors in the market today,” said HeartBeam CEO and Founder
Branislav Vajdic, PhD. “Our 12-lead ECG patch technology offers the
potential to bring a level of diagnostic accuracy consistent with
the current 12-lead ECG standard of care and could have a
disruptive effect on the ECG patch market with its ischemia
detection capability.”
The newly issued patent (No. 11,419,538 B2) expands on the
HeartBeam’s previously granted US patent (No. 11,071,490 B1) for a
12-lead ECG patch monitor technology. The patch patent follows
HeartBeam’s already granted core patents for remote detection of
heart attacks. These two issued patch patents significantly
increase HeartBeam’s intellectual property footprint, and they
further widen the impact HeartBeam’s technology could have on
cardiac patients and their physicians.
“The ECG monitors available today are primarily used for
detection of abnormal heart rhythms associated with atrial
fibrillation or syncope,” said Martin Burke, DO, FACC, cardiac
electrophysiologist and chief scientific officer of the CorVita
Science Foundation, which holds The Rory Childers Electrocardiology
Research Center and Fellowship program. “A 12-lead ECG patch would
provide additional information to aid in diagnosing conditions such
as ACS or more specific arrhythmias that current single-lead
patches cannot accurately detect.”
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company
that has developed the first and only 3D-vector ECG platform for
heart attack detection anytime, anywhere. By applying a suite of
proprietary algorithms to simplify vector electrocardiography
(VECG), the HeartBeam platform enables patients and their
clinicians to determine if symptoms are due to a heart attack,
quickly and easily, so care can be expedited, if required.
HeartBeam has two patented products in development. HeartBeam AIMI™
is software for acute care settings that provides a 3D comparison
of baseline and symptomatic 12-lead ECG to more accurately identify
a heart attack. HeartBeam AIMIGo™ is the first and only credit
card-sized 12-lead output ECG device coupled with a smart phone app
and cloud-based diagnostic software system to facilitate remote
heart attack detection. HeartBeam AIMI and AIMIGo have not yet been
cleared by the US Food and Drug Administration (FDA) for marketing
in the USA or other geographies. For more information, visit
HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our in our Forms 10-K, 10-Q and other reports filed with the SEC
and available at www.sec.gov. We urge you to consider those risks
and uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220915005195/en/
Investor Relations Contact: Chris Tyson Executive Vice
President MZ North America Direct: 949-491-8235 BEAT@mzgroup.us
www.mzgroup.us
Media Contact: Capwell Communications
media@capwellcomm.com 949-999-3303
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Apr 2023 to Apr 2024